Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients with Dry Eye After Trans-PRK

NCT ID: NCT06852105

Last Updated: 2025-02-28

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 76 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-02-28
• Study Completion Date: 2026-05-31

Brief Summary

The prevalence of refractive ametropia is rising year by year. Refractive surgery has become the main approach for adults to correct refractive ametropia, and postoperative complications have aroused extensive attention from clinicians. Dry eye after refractive surgery is one of the postoperative complications, which is an important cause of affecting the postoperative visual quality and satisfaction of patients. It was reported that 3% diquafosol (DQS) and 0.1% hyaluronic acid (HA) can relieve dry eye symptoms. This study aims to compare the efficacy of 3% DQS and 0.1% HA in treating dry eye after Trans-PRK

Detailed Description

The development of corneal refractive surgery is rapid, but the complications are still inevitable; postoperative dry eye is one of them. Dry eye after refractive surgery will affect not only the patient's postoperative satisfaction but also the patient's postoperative visual quality, resulting in blurred vision, not lasting vision, and other problems. The occurrence of postoperative dry eye is mainly due to using anesthetics during operation; corneal nerve injury and cell apoptosis; changes in corneal curvature; postoperative medication, and so on. The patient's bad living habits may aggravate the degree of postoperative dry eye.

Diquafosol sodium is a P2Y2 receptor agonist. P2Y2 receptors are present on conjunctival and corneal epithelial cells, among others, on the ocular surface. When diquafosol sodium is used, it can activate P2Y2 receptors on these cells. This activation triggers the opening of intracellular signaling pathways that stimulate tear secretion. Normal tear secretion is important for corneal nerve repair because tears contain a variety of nutrients and growth factors. In the state of dry eye, the inflammatory factors on the ocular surface increase, and the stability of the tear film decreases. Diquafosol sodium can help to restore the stability of tear film by promoting tear secretion. A stable tear film reduces corneal nerve stimulation by inflammatory factors on the ocular surface. A large area of corneal nerves is injured during Trans-PRK surgery, and no study has shown that diquafosol sodium has a role in nerve recovery after Trans-PRK Hyaluronic acid (HA) lubricates, relieving dry eyes, astringent eyes, and eye fatigue. It can also flush and dilute inflammatory mediators on the ocular surface, reduce tear osmotic pressure, promote ocular surface epithelial healing, and promote ocular surface fibronectin secretion and deposition.

This study aims to compare the efficacy of 3% diquafosol and 0.1% hyaluronic acid in treating dry eye after Trans-PRK. The observation of changes in corneal nerves and immune-inflammatory cells was added, aiming to observe the repair effect of difossol sodium on corneal nerves.

Conditions

Dry Eye; Tear Break-Up Time

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: SINGLE

Study Groups

Study group

dry eye patients after Trans-PRK

Group Type: OTHER

3% Diquafosol Sodium Eye Drops

Intervention Type: DRUG

3% Diquafosol Sodium Eye Drops were instilled into the inferior conjunctival vault of both eyes

Control group

dry eye patients after Trans-PRK

Group Type: OTHER

0.1% hyaluronic acid

Intervention Type: DRUG

0.1% sodium hyaluronate eye drops were instillation into the inferior conjunctival vault of both eyes

Interventions

3% Diquafosol Sodium Eye Drops

3% Diquafosol Sodium Eye Drops were instilled into the inferior conjunctival vault of both eyes

Intervention Type: DRUG

0.1% hyaluronic acid

0.1% sodium hyaluronate eye drops were instillation into the inferior conjunctival vault of both eyes

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age 18-40 years.
• The refractive status should be maintained at least for more than 2 years, during which the annual increase in myopia should be controlled within 0.50 D.
• Pherical equivalent (SE) ≤-6.00D, astigmatic power≤-2.00D.
• Best corrected vision before surgery≥1.0.
• Patients should stop wearing soft contact lenses for at least 2 weeks and hard contact lenses for at least 4 weeks before surgery.

Postoperative corneal stromal thickness was preserved (280 μm).

Exclusion Criteria

• Suspected of having keratoconus, a definite diagnosis of keratoconus, or another type of corneal dilatation disease.
• There is active inflammation or symptoms of infection in the eye.
• The thickness of the cornea does not meet the preset cutting depth requirement: the thickness of the central cornea should be greater than 450 μm, and the thickness of the central corneal stroma remaining under the corneal flap should be maintained above 250 μm after the intended cutting (280 μm recommended).
• Dry eye.
• There are serious lesions in the accessory structures of the eye, such as defects or deformations of the eyelids.
• People with uncontrolled systemic connective tissue diseases and autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

He Eye Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Guanghao Qin Principal Investigator

Role: CONTACT

qinguanghao2020@163.com

+86-1884266442

References

Zaabaar E, Asiamah R, Kyei S, Ankamah S. Myopia control strategies: A systematic review and meta-meta-analysis. Ophthalmic Physiol Opt. 2025 Jan;45(1):160-176. doi: 10.1111/opo.13417. Epub 2024 Nov 12.

Reference Type: BACKGROUND

PMID: 39530399 (View on PubMed)

Du Y, Di Y, Yang S, Li Y. Analysis of the changes in corneal optical density following small incision lenticule extraction for myopia and related influencing factors. Photodiagnosis Photodyn Ther. 2024 Dec;50:104397. doi: 10.1016/j.pdpdt.2024.104397. Epub 2024 Nov 9.

Reference Type: BACKGROUND

PMID: 39528007 (View on PubMed)

Mu J, Zhong H, Jiang M, Wang J, Zhang S. Development of a nomogram for predicting myopia risk among school-age children: a case-control study. Ann Med. 2024 Dec;56(1):2331056. doi: 10.1080/07853890.2024.2331056. Epub 2024 Mar 20.

Reference Type: BACKGROUND

PMID: 38507901 (View on PubMed)

Zhao L, Zhang Y, Duan H, Yang T, Ma B, Zhou Y, Chen J, Chen Y, Qi H. Clinical Characteristic and Tear Film Biomarkers After Myopic FS-LASIK: 1-Year Prospective Follow-up. J Refract Surg. 2024 Aug;40(8):e508-e519. doi: 10.3928/1081597X-20240514-05. Epub 2024 Sep 1.

Reference Type: BACKGROUND

PMID: 39120023 (View on PubMed)

Hou X, Chen P, Yu N, Luo Y, Wei H, Zhuang J, Yu K. A Comparative and Prospective Study of Corneal Consumption and Corneal Biomechanics After SMILE and FS-LASIK Performed on the Contralateral Eyes With High Myopic Astigmatism. Transl Vis Sci Technol. 2024 Nov 4;13(11):29. doi: 10.1167/tvst.13.11.29.

Reference Type: BACKGROUND

PMID: 39576656 (View on PubMed)

Yang F, Yang Z, Zhao S, Huang Y. To Investigate the Changes in Corneal Curvature and Its Correlation with Corneal Epithelial Remodeling After Trans-PRK and FS-LASIK. Curr Eye Res. 2024 Oct;49(10):1061-1067. doi: 10.1080/02713683.2024.2361728. Epub 2024 Jun 12.

Reference Type: BACKGROUND

PMID: 38867491 (View on PubMed)

Su B, Cho P, Vincent SJ, Zheng J, Chen J, Ye C, Wang T, Zhang J, Zhang K, Lu F, Jiang J. Novel Lenslet-ARray-Integrated Spectacle Lenses for Myopia Control: A 1-Year Randomized, Double-Masked, Controlled Trial. Ophthalmology. 2024 Dec;131(12):1389-1397. doi: 10.1016/j.ophtha.2024.07.002. Epub 2024 Jul 6.

Reference Type: BACKGROUND

PMID: 38972357 (View on PubMed)

Other Identifiers

PRK2025

Identifier Type: -

Identifier Source: org_study_id